New injection after liver ablation aims to stop colorectal cancer in its tracks

This study tests whether a new drug called IP-001, injected into the liver after standard heat-based tumor destruction, can help prevent colorectal cancer from coming back. About 717 adults with colorectal cancer that has spread only to the liver will be randomly assigned to receive either standard ablation alone or ablation plus a low or high dose of IP-001. The goal is to see if the injection activates the immune system to find and destroy any remaining cancer cells, reducing the risk of recurrence and spread.